CompanyHealth
NGM Biopharmaceuticals
NGM Biopharmaceuticals is a private South San Francisco biotech translating biology into first-in-class medicines, anchored by its GDF15/GFRAL antagonist NGM120 in Phase 2 trials for cancer cachexia and hyperemesis gravidarum.
2007Founded
South San FranciscoHQ
~$135M equity (approx. $1.55/share)Take-private acquisition
biotechbiopharmaceuticaldrug discoveryoncologycancer cachexiahyperemesis gravidarum